Skip to main content
. 2015 May 8;94(18):e673. doi: 10.1097/MD.0000000000000673

FIGURE 1.

FIGURE 1

Prevalence of episodic/interrupted therapy, concomitant IMM therapy, and Jewish Ashkenazi ethnicity among patients who developed ATI versus those who did not. ATI = antibodies to infliximab, IMM = immunomodulators.